3-Methoxy-2,4-dimethyl-pentan | 57132-05-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Methoxy-2,4-dimethyl-pentan
• 英文别名: 3-Methoxy-2,4-dimethylpentane
• CAS: 57132-05-5
• 化学式: C₈H₁₈O
• 分子量: 130.23
• InChiKey: JOMXUCNFIMRRLL-UHFFFAOYSA-N

物化性质

• 沸点：
  124-125 °C
• 密度：
  0.774±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  甲醇 、 2,4-二甲基-3-戊酮 在 platinum(IV) oxide 盐酸 、 氢气 作用下， 生成 3-Methoxy-2,4-dimethyl-pentan
  参考文献：
  名称：

  1072.醚的一般合成

  摘要：

  DOI：

  10.1039/jr9630005598

文献信息

• KYNURENINE PRODUCTION INHIBITOR
  申请人：Amishiro Nobuyoshi

  公开号：US20110237584A1

  公开（公告）日：2011-09-29

  Provided is a kynurenine production inhibitor comprising a nitrogen-containing heterocyclic compound represented by formula (I): (wherein R 50 and R 51 may be the same or different and each represent a hydrogen atom or the like, G 1 and G 2 may be the same or different and each represent a nitrogen atom or the like, X represents formula (III): (wherein m 1 and m 2 may be the same or different and each represent an integer of 0 or 1, Y represents an oxygen atom or the like, and R 6 and R 7 may be the same or different and each represent a hydrogen atom or the like), R 1 represents optionally substituted lower alkyl or the like, R 2 represents a hydrogen atom or the like, and R 3 represents optionally substituted lower alkyl or the like), and the like.

  提供的是一种色氨酸代谢抑制剂，包括由式(I)表示的含氮杂环化合物：（其中R50和R51可以相同也可以不同，每个代表氢原子或类似物，G1和G2可以相同也可以不同，每个代表氮原子或类似物，X表示式(III)：（其中m1和m2可以相同也可以不同，每个代表0或1的整数，Y表示氧原子或类似物，R6和R7可以相同也可以不同，每个代表氢原子或类似物），R1表示可选择地取代的低碳烷基或类似物，R2表示氢原子或类似物，R3表示可选择地取代的低碳烷基或类似物），等等。
• COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM
  申请人：Takayama Masami

  公开号：US20090318513A1

  公开（公告）日：2009-12-24

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  一种由通式（I）表示的化合物：其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。该化合物为一种前药、药物可接受的盐或其溶剂。
• Compounds exhibiting thrombopoietin receptor agonism
  申请人：Takayama Masami

  公开号：US20070043087A1

  公开（公告）日：2007-02-22

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  化合物的一般式(I)表示的复合物，其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。这是一个前药、药物可接受的盐或其溶剂。
• REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS
  申请人：Liotta Charles L.

  公开号：US20130096317A1

  公开（公告）日：2013-04-18

  The embodiments described herein provide a reduction of an aldehyde or a ketone, such as a Meerwein-Ponnorf-Verley (MPV) reaction of an aldehyde or ketone. In some embodiments, the reaction occurs in the presence of Al[OC(CH 3 ) 3 ]. In some embodiments, the reaction occurs in the presence of an aprotic solvent. In some embodiments, the aldehyde or ketone is an amino aldehyde or an amino ketone wherein the amine is group is protected such that the nitrogen of the amine has no proton. Other embodiments related to compositions and compounds related to the reduction reaction, or to the preparation or use of the aldehyde, the ketone, or the resulting alcohol.

  本文所述的实施例提供了对醛或酮的还原，例如醛或酮的Meerwein-Ponnorf-Verley(MPV)反应。在某些实施例中，反应发生在Al [OC (CH3) 3]的存在下。在某些实施例中，反应发生在无极溶剂的存在下。在某些实施例中，醛或酮是氨基醛或氨基酮，其中氨基保护基团保护，使得氨基的氮没有质子。其他实施例涉及与还原反应相关的组合物和化合物，或与醛、酮或所得的醇的制备或使用相关的实施例。
• Immunosuppressant peptides
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0297456A2

  公开（公告）日：1989-01-04

  Novel peptides having a fragment containing 2 or 3 Arg or Lys residues and having a fragment containing 2 or 3 Gly, Leu, Ile, or Thr residues adjacent to the carboxy end of the first fragment and having amino and carboxy tails consisting of chains made up of any amino acids are immunosuppressant agents and can suppress the lymphocyte system by suppressing lymphocyte proliferation. The formula is as follows:       Tn-A-B-C-D-Tc wherein       Tn is an amino terminal residue selected from hydrogen, one or two alkyl groups of from 1 to 6 carbon atoms, one or two acyl groups of from 2 to 10 carbon atoms, carbobenzyloxy, and t-butyloxy­carbonyl;       A is a peptide fragment containing from 3 to 12 residues of any amino acid;       B is a peptide fragment containing 2 or 3 amino acid residues selected from Arg and Lys;       C is a peptide fragment containing 2 or 3 amino acid residues selected from Gly, Leu, Ile, and Thr;       D is a peptide fragment containing from 1 to 12 residues of any amino acid; and       Tc is a carboxy terminal residue selected from OH, (C₁-C₆)alkoxy, amino, mono- or di-(C₁-C₄)alkyl substituted amino, and benzylamino.

  新型多肽具有含有 2 或 3 个 Arg 或 Lys 残基的片段，以及与第一个片段的羧基端相邻的含有 2 或 3 个 Gly、Leu、Ile 或 Thr 残基的片段，并具有由任意氨基酸组成的链的氨基和羧基尾部，是一种免疫抑制剂，可通过抑制淋巴细胞增殖来抑制淋巴细胞系统。 其计算公式如下 Tn-A-B-C-D-Tc 其中 Tn 是氨基末端残基，选自氢、一个或两个 1 至 6 个碳原子的烷基、一个或两个 2 至 10 个碳原子的酰基、苄氧羰基和 t-丁氧羰基； A 是含有 3 至 12 个氨基酸残基的肽片段； B 是含有 2 或 3 个选自 Arg 和 Lys 的氨基酸残基的肽片段； C 是含有 2 或 3 个选自 Gly、Leu、Ile 和 Thr 的氨基酸残基的肽片段； D 是含有 1 至 12 个任意氨基酸残基的肽片段；以及 Tc 是羧基末端残基，选自 OH、(C₁-C₆)烷氧基、氨基、单-或二-(C₁-C₄)烷基取代的氨基和苄基氨基。